Novartis AG
Use of IL-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Abstract:

The present disclosure relates to methods, uses, medicaments, pharmaceutical formulations, dosage forms, and kits for inhibiting the progression of structural damage in psoriatic arthritis (PsA) patients using Interleukin-17 (IL-17) antagonists, e.g., IL-17 antibodies and antigen-binding fragments thereof, e.g., secukinumab.